ArticleAntibodies (Basel, Switzerland)2023

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study.

Shinya Murata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.